» Articles » PMID: 8620665

Determination of a New 5-lipoxygenase Inhibitor, Zileuton, and Its Inactive N-dehydroxylated Metabolite in Plasma by High Performance Liquid Chromatography

Overview
Specialty Pharmacology
Date 1995 Jan 1
PMID 8620665
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

A rapid and sensitive assay was developed for the measurement of plasma concentrations of zileuton racemate, a potent inhibitor of 5-lipoxygenase. Zileuton and its inactive N-dehydroxylated metabolite were extracted from human, monkey, and rat plasma by use of a solid-phase extraction column (Analytichem Bond Elut). The compounds were then separated by reverse-phase high performance liquid chromatography (HPLC) on a Supelcosil LC-18 column and quantified on the basis of ultraviolet absorption at 260nm relative to an internal standard. The extraction recovery of zileuton, as determined by HPLC assay, was 77.9 +/- 1.7%. Recovery of the metabolite was 85.8 +/- 0.7%. Calibration curves for both compounds were linear over the zileuton concentration range 0.01 to 10.0 mg/L (correlation coefficients > 0.987), while the intra- and interassay coefficients of variation were < 15.6%. In practice, > 97% of blinded daily spiked control samples for zileuton and > 90% of those for the metabolite were within 10% of their target concentrations.

Citing Articles

Development and validation of a liquid chromatography-mass spectrometry method for the determination of zileuton in human plasma.

Prakash K, Adiki S, Kalakuntla R Sci Pharm. 2015; 82(3):571-83.

PMID: 25853069 PMC: 4339974. DOI: 10.3797/scipharm.1402-19.


Effect of zileuton on theophylline pharmacokinetics.

Granneman G, Braeckman R, Locke C, CAVANAUGH J, Dube L, Awni W Clin Pharmacokinet. 1995; 29 Suppl 2:77-83.

PMID: 8620674 DOI: 10.2165/00003088-199500292-00011.


The effect of food on the pharmacokinetics of zileuton.

Awni W, CAVANAUGH J, Witt G, Granneman G, Dube L Clin Pharmacokinet. 1995; 29 Suppl 2:62-6.

PMID: 8620672 DOI: 10.2165/00003088-199500292-00009.


The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton.

Awni W, CAVANAUGH J, Braeckman R, Chu S, Patterson K, MACHINIST J Clin Pharmacokinet. 1995; 29 Suppl 2:49-61.

PMID: 8620671 DOI: 10.2165/00003088-199500292-00008.


The pharmacokinetics of zileuton in healthy young and elderly volunteers.

Braeckman R, Granneman G, Locke C, MACHINIST J, Cavannaugh J, Awni W Clin Pharmacokinet. 1995; 29 Suppl 2:42-8.

PMID: 8620670 DOI: 10.2165/00003088-199500292-00007.


References
1.
Samuelsson B . Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983; 220(4597):568-75. DOI: 10.1126/science.6301011. View

2.
Piper P . Formation and actions of leukotrienes. Physiol Rev. 1984; 64(2):744-61. DOI: 10.1152/physrev.1984.64.2.744. View